A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2 | Publicación